Abstract
In the CheckMate 275 study, composite biomarkers appear to better predict response to immunotherapy over individual ones. Nevertheless, the path forward needs consensus guidelines for biomarker interpretation. Thereafter, prospective validation with real-time, serial biospecimen collection along with the development of composite biomarker models leads to the goal of personalized therapy.
See related article by Galsky et al., p. 5120
©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.